NeutraSiga Therapeutics, Inc
Human protein platform
Underdevelopment of the neonatal immune system predisposes infants to inflammatory disorders e.g., Necrotizing Enterocolitis (NEC)
Alterations early in life influence disease outcomes later in life, and human proteins found in human milk can improve early life outcomes.
Human milk is a drug
Human Immune Milk™ therapeutics
NeutraSiga is developing Human Immune Milk™ therapeutics derived from donor milk, recombinant biotechnology and cell cultured human milk.
NeutraSiga is advancing pre-clinical studies for Human Immune Milk™ Therapeutics to improve anti-microbial, anti-inflammatory and growth acceleration outcomes in preterm infants with human proteins.
Corporate and Press Contact
available from 10:00 – 17:00
Address 630 Pena Dr., Davis, CA 95618